APA (7th ed.) Citation
(2026). TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer. PLOS ONE.
Chicago Style (17th ed.) Citation
"TNFRSF17 as a Complementary Biomarker to PD-L1 for Predicting the Response to Immunotherapy in Urothelial Bladder Cancer." PLOS ONE 2026.
MLA (9th ed.) Citation
"TNFRSF17 as a Complementary Biomarker to PD-L1 for Predicting the Response to Immunotherapy in Urothelial Bladder Cancer." PLOS ONE, 2026.
Warning: These citations may not always be 100% accurate.